{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:31:43Z","timestamp":1777775503828,"version":"3.51.4"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Dense fine speckled (DFS) pattern is defined by very intense, heterogeneous speckled staining of nucleoplasms of interphase HEp-2 cells and chromosomal areas of metaphase cells. The association of Anti-DFS70 and rheumatologic signs, symptoms, and diagnosis were evaluated.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    One-hundred-eight anti-DFS70 positives who got consecutively admitted to the Rheumatology clinic between January and June 2020 were analyzed. The clinical and laboratory findings of positives for anti-DFS70 antibody were compared with those with DFS pattern ANA IFA staining rates. Also, anti-DFS70 positivity rates and their correlation with the DFS staining pattern were analyzed retrospectively in 1016 CTD patients.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The most common complaint was joint pain seen in 77 (71.3%) and the most common laboratory abnormality was RF-positivity observed in 10\/108 (9.3%) who had anti-DFS70 positivity. The most common ANA staining pattern was DFS (72\/108; 66.7%); one-third had other than DFS. No statistical significance was found for the association of any of the rheumatological complaints and laboratory findings with the DFS staining pattern. ANA analysis was performed in a total of 964\/1016 (94.88%) CTD patients and 44 (4.56%) of these positive for anti-DFS70. The correlation coefficient showed good correlations between the DFS pattern staining and anti-DFS70 antibody positivity (r=+0.773, p&lt;0.001).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Anti-DFS70-positives have a low rate of CTD. A low anti-DFS70 positivity rate was observed in patients with CTD. As such, it can be considered that anti-DFS70 does not predict CTD or even excludes it.\n                  <\/jats:p>","DOI":"10.2478\/rjim-2021-0029","type":"journal-article","created":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T19:06:55Z","timestamp":1627844815000},"page":"66-76","source":"Crossref","is-referenced-by-count":0,"title":["Anti-dense fine speckled (DFS) antibody: its staining pattern in indirect immunofluorescence and its clinical relevance"],"prefix":"10.2478","volume":"60","author":[{"given":"Samet","family":"Karahan","sequence":"first","affiliation":[{"name":"Kayseri City Education and Research Hospital , Department of Internal Medicine, Division of Rheumatology , Kayseri , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-8722","authenticated-orcid":false,"given":"\u015eerife","family":"Emre","sequence":"additional","affiliation":[{"name":"Kayseri City Education and Research Hospital, Internal Medicine , Kayseri , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hatice T.","family":"H\u00f6rmet-\u00d6z","sequence":"additional","affiliation":[{"name":"Kayseri City Education and Research Hospital , Department of Microbiology , Kayseri , Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"2026042913133206289_j_rjim-2021-0029_ref_001","doi-asserted-by":"crossref","unstructured":"1. P\u0130SETSKY DS, L\u0130PSKY PE. New insights into the role of antinuclear antibodies in systemic lupus erythematosus. Nat Rev Rheumatol. 2020 Oct;16(10):565\u201379.10.1038\/s41584-020-0480-7","DOI":"10.1038\/s41584-020-0480-7"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_002","unstructured":"2. NOSAL RS, SUPERV\u0130LLE SS, VARACALLO M. Biochemistry, Antinuclear Antibodies (ANA). In Treasure Island (FL); 2021."},{"key":"2026042913133206289_j_rjim-2021-0029_ref_003","doi-asserted-by":"crossref","unstructured":"3. CHAN EKL, DAMO\u0130SEAUX J, CARBALLO OG, CONRAD K, DE MELO CRUV\u0130NEL W, FRANCESCANTON\u0130O PLC, et al. Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. Front Immunol. 2015;6:412.10.3389\/fimmu.2015.00412","DOI":"10.3389\/fimmu.2015.00412"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_004","doi-asserted-by":"crossref","unstructured":"4. GANAPATHY V, CAS\u0130ANO CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis and rheumatism. United States; 2004;50:684\u20138.","DOI":"10.1002\/art.20095"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_005","doi-asserted-by":"crossref","unstructured":"5. OCHS RL, STE\u0130N TWJ, PEEBLES CL, G\u0130TTES RF, TAN EM. Autoantibodies in interstitial cystitis. J Urol. 1994;151(3):587\u201392.10.1016\/S0022-5347(17)35023-1","DOI":"10.1016\/S0022-5347(17)35023-1"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_006","doi-asserted-by":"crossref","unstructured":"6. B\u0130ZZARO N, TONUTT\u0130 E, V\u0130SENT\u0130N\u0130 D, ALESS\u0130O MG, PLATZGUMMER S, MOROZZ\u0130 G, et al. Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann N Y Acad Sci. 2007;1107:174\u201383.10.1196\/annals.1381.019","DOI":"10.1196\/annals.1381.019"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_007","doi-asserted-by":"crossref","unstructured":"7. DAN\u0130ELS T, ZHANG J, GUT\u0130ERREZ I, ELL\u0130OT ML, YAMADA B, HEEB MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF\/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62(1):14\u201326.10.1002\/pros.20112","DOI":"10.1002\/pros.20112"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_008","doi-asserted-by":"crossref","unstructured":"8. OCHS RL, MURO Y, S\u0130 Y, GE H, CHAN EK, TAN EM. Autoantibodies to DFS 70 kd\/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 Pt 1):1211\u201320.10.1067\/mai.2000.107039","DOI":"10.1067\/mai.2000.107039"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_009","doi-asserted-by":"crossref","unstructured":"9. AYAK\u0130 M, OHOGURO N, AZUMA N, MAJ\u0130MA Y, YATA K, IBARAK\u0130 N, et al. Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity. 2002;35(5):319\u201327.10.1080\/0891693021000003198","DOI":"10.1080\/0891693021000003198"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_010","doi-asserted-by":"crossref","unstructured":"10. OKAMOTO M, OGAWA Y, WATANABE A, SUG\u0130URA K, SH\u0130MOMURA Y, AOK\u0130 N, et al. Autoantibodies to DFS70\/LEDGF are increased in alopecia areata patients. J Autoimmun. 2004;23(3):257\u201366.10.1016\/j.jaut.2004.07.004","DOI":"10.1016\/j.jaut.2004.07.004"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_011","doi-asserted-by":"crossref","unstructured":"11. YAMADA K, SENJU S, SH\u0130NOHARA T, NAKATSURA T, MURATA Y, ISH\u0130HARA M, et al. Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett. 2001;78(3):161\u20138.10.1016\/S0165-2478(01)00243-7","DOI":"10.1016\/S0165-2478(01)00243-7"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_012","doi-asserted-by":"crossref","unstructured":"12. YUMUK Z, DEM\u0130R M. Clinical value of anti-DFS70 antibodies in a cohort of patients undergoing routine antinuclear antibodies testing. J Immunol Methods. 2020;480:112754.10.1016\/j.jim.2020.11275432057435","DOI":"10.1016\/j.jim.2020.112754"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_013","unstructured":"13. LA JEON Y, KANG SY, LEE W-I, K\u0130M MH. Clinical Aspects of the Dense Fine Speckled Pattern in Indirect Immunofluorescence-Antinuclear Antibody Screening and Its Association with DFS70 Autoantibodies. Ann Clin Lab Sci. 2019;49(4):496\u2013502."},{"key":"2026042913133206289_j_rjim-2021-0029_ref_014","doi-asserted-by":"crossref","unstructured":"14. PASHN\u0130NA IA, KR\u0130VOLAPOVA IM, FEDOTK\u0130NA T V, RYABKOVA VA, CHERESHNEVA M V, CHUR\u0130LOV LP, et al. Antinuclear Autoantibodies in Health: Autoimmunity Is Not a Synonym of Autoimmune Disease. Antibodies (Basel, Switzerland). 2021;10(1).10.3390\/antib10010009800615333668697","DOI":"10.3390\/antib10010009"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_015","doi-asserted-by":"crossref","unstructured":"15. SEEL\u0130G CA, BAUER O, SEEL\u0130G H-P. Autoantibodies Against DFS70\/LEDGF Exclusion Markers for Systemic Autoimmune Rheumatic Diseases (SARD). Clin Lab. 2016;62(4):499\u2013517.10.7754\/Clin.Lab.2015.150905","DOI":"10.7754\/Clin.Lab.2015.150905"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_016","doi-asserted-by":"crossref","unstructured":"16. MULHEARN B, TANSLEY SL, MCHUGH NJ. Autoantibodies in connective tissue disease. Best Pract Res Clin Rheumatol. 2020;34(1):101462.10.1016\/j.berh.2019.10146231848055","DOI":"10.1016\/j.berh.2019.101462"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_017","doi-asserted-by":"crossref","unstructured":"17. ALME\u0130DA GONZ\u00c1LEZ D, ROCES VARELA A, MARCEL\u0130NO RODR\u00cdGUEZ I, GONZ\u00c1LEZ VERA A, DELGADO S\u00c1NCHEZ M, AZNAR ESQU\u0130VEL A, et al. Anti-dsDNA antibodies in systemic lupus erythematosus: A combination of two quantitative methods and the ANA pattern is the most efficient strategy of detection. J Immunol Methods. 2015;427:30\u20135.10.1016\/j.jim.2015.09.00326407840","DOI":"10.1016\/j.jim.2015.09.003"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_018","doi-asserted-by":"crossref","unstructured":"18. MAHLER M, PARKER T, PEEBLES CL, ANDRADE LE, SWART A, CARBONE Y, et al. Anti-DFS70\/LEDGF Antibodies Are More Prevalent in Healthy Individuals Compared to Patients with Systemic Autoimmune Rheumatic Diseases. J Rheumatol 2012;39(11):210410.3899\/jrheum.12059822942262","DOI":"10.3899\/jrheum.120598"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_019","unstructured":"19. PEPMUELLER PH. Undifferentiated Connective Tissue Disease, Mixed Connective Tissue Disease, and Overlap Syndromes in Rheumatology. Mo Med. 2016;113(2):136\u201340."},{"key":"2026042913133206289_j_rjim-2021-0029_ref_020","doi-asserted-by":"crossref","unstructured":"20. INFANT\u0130NO M, SHOVMAN O, P\u00c9REZ D, MANFRED\u0130 M, GROSS\u0130 V, BENUCC\u0130 M, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: what\u2019s on the horizon? Rheumatology (Oxford). 2018;57(7):1293\u20138.10.1093\/rheumatology\/key01229618128","DOI":"10.1093\/rheumatology\/key012"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_021","doi-asserted-by":"crossref","unstructured":"21. ROMERO-\u00c1LVAREZ V, ACERO-MOL\u0130NA DA, BELTR\u00c1N-OSTOS A, BELLO-GUALTEROS JM, ROMERO-S\u00c1NCHEZ C. Frequency of ANA\/DFS70 in Relatives of Patients with Rheumatoid Arthritis Compared to Patients with Rheumatoid Arthritis and a Healthy Population, and its Association with Health Status. Reumatol Clin. 2021;17(2):67\u201373.10.1016\/j.reuma.2019.02.00331104879","DOI":"10.1016\/j.reumae.2019.02.008"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_022","doi-asserted-by":"crossref","unstructured":"22. HAYASH\u0130 N, UTO K, IMAN\u0130SH\u0130 A, SUG\u0130YAMA D, MOR\u0130NOBU A, SAEGUSA J. Prevalence of anti-dense fine speckled 70 antibodies in healthy individuals and patients with antinuclear antibody-associated autoimmune rheumatic diseases in Japan. Medicine (Baltimore). 2021;100(9):e24556.10.1097\/MD.0000000000024556793920033655922","DOI":"10.1097\/MD.0000000000024556"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_023","doi-asserted-by":"crossref","unstructured":"23. MURO Y, SUG\u0130URA K, MOR\u0130TA Y, TOM\u0130TA Y. High concomitance of disease marker autoantibodies in anti-DFS70\/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus. 2008;17(3):171\u20136.10.1177\/096120330708631118372356","DOI":"10.1177\/0961203307086311"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_024","doi-asserted-by":"crossref","unstructured":"24. WATANABE A, KODERA M, SUG\u0130URA K, USUDA T, TAN EM, TAKASAK\u0130 Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892\u2013900.10.1002\/art.2009615022332","DOI":"10.1002\/art.20096"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_025","unstructured":"25. CHO\u0130 MY, CLARKE AE, ST P\u0130ERRE Y, HANLY JG, UROW\u0130TZ MB, ROMERO-D\u0130AZ J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26(10):1051\u20139.10.1177\/096120331769243728420054"},{"key":"2026042913133206289_j_rjim-2021-0029_ref_026","doi-asserted-by":"crossref","unstructured":"26. KANG SY, LEE WI, K\u0130M MH, LA JEON Y. Clinical use of anti-DFS70 autoantibodies. Rheumatol Int. 2019;39(8):1423\u20139.10.1007\/s00296-019-04299-430972541","DOI":"10.1007\/s00296-019-04299-4"}],"container-title":["Romanian Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/rjim-2021-0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T18:11:03Z","timestamp":1777486263000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/rjim-2021-0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,1]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,17]]},"published-print":{"date-parts":[[2022,3,1]]}},"alternative-id":["10.2478\/rjim-2021-0029"],"URL":"https:\/\/doi.org\/10.2478\/rjim-2021-0029","relation":{},"ISSN":["2501-062X"],"issn-type":[{"value":"2501-062X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,1]]}}}